07:21 AM EDT, 09/04/2024 (MT Newswires) -- Eli Lilly and Company ( LLY ) and EVA Pharma said Wednesday that they have entered into an agreement to expand access to baricitinib to about 20,000 people across 49 low- to middle-income countries in Africa by 2030 to treat of various immunological diseases.

Lilly said it will license certain baricitinib manufacturing knowledge to allow EVA Pharma to manufacture and supply the treatment for rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.

EVA Pharma's dedicated high-containment facility is expected to start sales of the locally manufactured baricitinib by 2026 to various African countries, the companies said.

Price: 946.52, Change: -10.01, Percent Change: -1.05